Therapeutic Asset Ratings
236 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Montanide Isa 51
Hepatocellular Carcinoma
National Cancer Institute, Naples
P1
C
(37)
Mrna Hbv/Tcr T-Cells
Hepatocellular Carcinoma
Lion TCR Pte. Ltd.
P1
C
(37)
mt-303
Hepatocellular Carcinoma
Myeloid Therapeutics
P1
C
(37)
mt-8421
Hepatocellular Carcinoma
Molecular Templates, Inc.
P1
C
(37)
Naptumomab Estafenatox
Hepatocellular Carcinoma
NeoTX Therapeutics Ltd.
P1
C
(37)
Nocardia Rubra Cell Wall Skeleton
Hepatocellular Carcinoma
Wan-Guang Zhang
P1
C
(37)
np-101
Hepatocellular Carcinoma
University of Florida
P1
C
(37)
np137
Hepatocellular Carcinoma
University Hospital, Grenoble
P1
C
(37)
pb101
Hepatocellular Carcinoma
Panolos Bioscience
P1
C
(37)
pf-08046054
Hepatocellular Carcinoma
Seagen, a wholly owned subsidiary of Pfizer
P1
C
(37)
PIN
Hepatocellular Carcinoma
Chinese PLA General Hospital
P1
C
(37)
QXL138AM
Hepatocellular Carcinoma
Nammi Therapeutics Inc
P1
C
(37)
Rd-Cy7 Fluorophore
Hepatocellular Carcinoma
Institute of Automation, Chinese Academy of Sciences
P1
C
(37)
Rocakinogene Sifuplasmid
Hepatocellular Carcinoma
National Cancer Institute (NCI)
P1
C
(37)
Sc-Car.Gpc3Xil15.21 Car T Cells
Hepatocellular Carcinoma
Seattle Children's Hospital
P1
C
(37)
Selinexor
Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
P1
C
(37)
Synov1.1
Hepatocellular Carcinoma
Beijing Syngentech Co., Ltd.
P1
C
(37)
Torl-4-500
Hepatocellular Carcinoma
TORL Biotherapeutics, LLC
P1
C
(37)
Ymn-A02
Hepatocellular Carcinoma
West China Hospital
P1
C
(37)
zw251
Hepatocellular Carcinoma
Zymeworks BC Inc.
P1
C
(37)
INCB 086550
Hepatocellular Carcinoma
Incyte Corporation
P2
C
(36)
Semaglutide
Hepatocellular Carcinoma
University of Arizona
Early P1
C
(34)
Tenofovir Amibufenamide
Hepatocellular Carcinoma
Ningbo No.2 Hospital
Early P1
C
(34)
HUMAN INTERLEUKIN 2 (IL2, T-CELL GROWTH FACTOR, TCGF) (2-133) VARIANT (A1 DELETED, PRO65>LYS, CYS125>SER), NON-GLYCOSYLATED, PRODUCED IN ESCHERICHIA COLI, CONJUGATED AT N6 OF K65 WITH A PEG DERIVATIVE (30KDA)
Hepatocellular Carcinoma
Sanofi
P2
C
(33)
Nanrilkefusp Alfa
Hepatocellular Carcinoma
SOTIO Biotech AG
P2
D
(30)
Showing 201 to 225 of 236 assets
Previous
Page 9 of 10
Next
